HOME >> MEDICINE >> NEWS
When crowded, things become stuff

Rockville, MD -- A special collection of articles devoted to "Crowding," a failure of object recognition, is currently being published by Journal of Vision, an online, free access publication of the Association for Research in Vision and Ophthalmology (ARVO). An object is "crowded" when clutter jumbles its appearance, making it impossible to identify.

Guest editors Denis Pelli, New York University; Patrick Cavanagh, Harvard University and Universit de Paris 5; Robert Desimone, Massachusetts Institute of Technology; Bosco Tjan, University of Southern California; and Anne Treisman, Princeton University, ask how much of the difficulty of seeing in a cluttered environment - long searches, slow reading, illusory conjunctions, and surround suppression - can be attributed to inappropriate integration of visual features.

"Does crowding affect what we see? Yes, every day," said Pelli. "Most of our visual field is peripheral and most of the world is cluttered, so most of what we see is crowded, unrecognized stuff. We talk about the things that we do recognize, but they are the exception."


'"/>

Contact: Elinore Tibbetts
etibbetts@arvo.org
240-221-2923
Association for Research in Vision and Ophthalmology
6-Mar-2007


Page: 1

Related medicine news :

1. MRI finds breast cancer before it becomes dangerous
2. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
3. Persistent smokers may have higher risk to become depressed than never smokers
4. How your brain helps you become a wine expert
5. Intelligent children more likely to become vegetarian
6. Socially isolated children may become unhealthy adults
7. Grueling four-day race becomes Stanford lab for cardiac experiments
8. Individuals with a family history of alcoholism: Will they too become alcoholics?
9. National ICD Registry becomes official database for Medicare
10. New strategies help depressed patients become symptom-free
11. Measuring artery repair cells could become new heart disease test

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: When crowded things become stuff

(Date:11/26/2014)... (PRWEB) November 26, 2014 The family ... $100,000 to the Mesothelioma Applied Research Foundation (Meso Foundation), ... Meso Foundation’s Patient Travel Grant Program . The ... is to create grant partnerships with organizations that can ... , Mr. Schulze is the founder and chairman emeritus ...
(Date:11/26/2014)... November 26, 2014 The American ... the Association’s new director of meetings and conferences. ... annual meeting, special events and conferences. , ... this post,” said AAA Executive Director Ed Liebow. ... enthusiasm and energy. She was recognized in January ...
(Date:11/26/2014)... Washington, DC (PRWEB) November 26, 2014 ... Inc.’s (AIS) independently published The AIS Report on Blue ... Inc. and WellPoint, Inc. on the varied strategies the ... costs and improve compliance with treatments for sleep apnea, ... The sleep disorder, because it’s linked to increased rates ...
(Date:11/26/2014)... Santa Rosa, California (PRWEB) November 26, 2014 ... be making never before seen reductions in prices of ... and Liposomal Vitamin D3 . Discounts ... only. , GI for Life’s proprietary ColoVite ... leading board-certified gastroenterologists to promote colon health. One easy-to-take ...
(Date:11/26/2014)... Anthropologists have identified concrete recommendations that ... Ebola, improve international support, and pave the way ... Africa. , The report, “Strengthening West African ... Insights,” will be made public during a press ... Fri., Dec. 5, 11 a.m., at the AAA ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... China, Nov. 26, 2014 China Nepstar Chain ... "Company"), a leading retail drugstore chain in China based ... its unaudited financial results for the third quarter ended September ... 30, 2014: , Same store sales increased by ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 million) ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
Cached News: